JPMorgan Ultra Short Income ETF vs Oruka Therapeutics Inc. Common Stock — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.29 (market cap $42.48B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B). The key difference: JPMorgan Ultra Short Income ETF is far larger — about 8.4× Oruka Therapeutics Inc. Common Stock's market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Ultra Short Income ETF for 47 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| JPST | ORKA | |
|---|---|---|
Market Cap | $42.48B | $5.08B |
Volume | 12,289,471 | 685,276 |
Sector | Fixed Income | Health |
52-Week High | $50.78 | $113.08 |
52-Week Low | $50.22 | $26.19 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | — | $4.21B |
Signals from Pluang's Aura AI — not financial advice
JPMorgan Ultra-Short Income ETF (JPST) trades at $50.31 with minimal daily movement, reflecting its ultra-short bond strategy focused on capital preservation. The technical picture shows bearish momentum with RSI indicators mixed, while fundamental data remains limited for this income-focused ETF. Recent news highlights institutional positioning changes and ongoing investor interest in ultrashort bond strategies amid rate uncertainty.
JPST offers investors exposure to high-quality, short-duration bonds with regular dividend distributions. The fund faces competition from similar ultrashort ETFs and sensitivity to Federal Reserve policy changes. Current market conditions favor cash-alternative strategies, though expense ratios and active management performance remain key considerations for investors seeking yield with minimal risk.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →